CagriSema
Overview
CagriSema is a fixed-ratio combination of cagrilintide, an amylin analog, and semaglutide, a GLP-1 receptor agonist, both delivered as peptides via subcutaneous injection. Cagrilintide acts on amylin receptors to reduce appetite and slow gastric emptying, while semaglutide enhances insulin secretion and suppresses glucagon. The combination is intended to achieve greater weight loss than either agent alone in the treatment of obesity.
Key Research Findings
Phase 2 trials presented in 2023 showed superior weight reduction with CagriSema compared to semaglutide monotherapy in adults with obesity. Adverse events were predominantly gastrointestinal and dose-related. Phase 3 studies are ongoing to evaluate efficacy and safety in larger cohorts and diverse populations.
Subcutaneous injection
In Clinical Trials
Interested in CagriSema?
Find a verified provider experienced with CagriSema protocols in your area. All providers are credentialed and use compliant sourcing.
Find a CagriSema ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.